Abstract Background. The 2014–2015 influenza season was distinguished by an epidemic
of antigenically-drifted A (H3N2) viruses and vaccine components identical to 2013–2014 …

Abstract The International Society for Influenza and other Respiratory Virus Diseases (isirv)
held its 4th Antiviral Group Conference at the University of Texas on 2–4 June, 2015. With …

Although randomized placebo-controlled trials (RCT) are critical to establish efficacy of
vaccines at the time of licensure, important remaining questions about vaccine effectiveness …

Multiple subtypes and many antigenic variants of influenza A virus (IAV) co-circulate in
swine in the USA, complicating effective use of commercial vaccines to control disease and …

Background: The test-negative design (TND) to evaluate influenza vaccine effectiveness is
based on patients seeking care for acute respiratory infection, with those who test positive …

Broadly neutralizing monoclonal antibodies (bNAbs) for viral infections, such as HIV,
respiratory syncytial virus (RSV), and influenza, are increasingly entering clinical …

The association of seasonal trivalent influenza vaccine (TIV) with increased infection by
2009 pandemic H1N1 (A (H1N1) pdm09) virus, initially observed in Canada, has elicited …

During the 2009/10 influenza A (H1N1) pdm09 pandemic, the five Nordic countries adopted
different approaches to pandemic vaccination. We compared pandemic vaccination …

Background Infants are at high risk for influenza illness, but are ineligible for vaccination
before 6 months. Transfer of maternal antibodies to the fetus has been demonstrated for …

Abstract Background Before pandemic H1N1 vaccines were available, the potential benefit
of existing seasonal trivalent inactivated influenza vaccines (IIV3s) against influenza due to …